Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

751 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Subbiah V, et al. Among authors: curigliano g. Lancet Diabetes Endocrinol. 2021 Aug;9(8):491-501. doi: 10.1016/S2213-8587(21)00120-0. Epub 2021 Jun 9. Lancet Diabetes Endocrinol. 2021. PMID: 34118198 Clinical Trial.
Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H, Tryfonidis K, Dal Lago L, Vuylsteke P, Curigliano G, Waters S, Brouwers B, Altintas S, Touati N, Cardoso F, Brain E. Wildiers H, et al. Among authors: curigliano g. Lancet Oncol. 2018 Mar;19(3):323-336. doi: 10.1016/S1470-2045(18)30083-4. Epub 2018 Feb 9. Lancet Oncol. 2018. PMID: 29433963 Clinical Trial.
Progresses Toward Precision Medicine in RET-altered Solid Tumors.
Belli C, Anand S, Gainor JF, Penault-Llorca F, Subbiah V, Drilon A, Andrè F, Curigliano G. Belli C, et al. Among authors: curigliano g. Clin Cancer Res. 2020 Dec 1;26(23):6102-6111. doi: 10.1158/1078-0432.CCR-20-1587. Epub 2020 Jul 14. Clin Cancer Res. 2020. PMID: 32665298 Free article. Review.
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, de Braud F, Prager GW, Greil R, Stein A, Fasolo A, Schellens JHM, Wen PY, Viele K, Boran AD, Gasal E, Burgess P, Ilankumaran P, Wainberg ZA. Subbiah V, et al. Among authors: curigliano g. Lancet Oncol. 2020 Sep;21(9):1234-1243. doi: 10.1016/S1470-2045(20)30321-1. Epub 2020 Aug 17. Lancet Oncol. 2020. PMID: 32818466 Clinical Trial.
Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours.
Bono P, Massard C, Peltola KJ, Azaro A, Italiano A, Kristeleit RS, Curigliano G, Lassen U, Arkenau HT, Hakulinen P, Garratt C, Ikonen T, Mustonen MVJ, Rodon JA. Bono P, et al. Among authors: curigliano g. ESMO Open. 2020 Dec;5(6):e001081. doi: 10.1136/esmoopen-2020-001081. ESMO Open. 2020. PMID: 33262202 Free PMC article. Clinical Trial.
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.
Belli C, Penault-Llorca F, Ladanyi M, Normanno N, Scoazec JY, Lacroix L, Reis-Filho JS, Subbiah V, Gainor JF, Endris V, Repetto M, Drilon A, Scarpa A, André F, Douillard JY, Curigliano G. Belli C, et al. Among authors: curigliano g. Ann Oncol. 2021 Mar;32(3):337-350. doi: 10.1016/j.annonc.2020.11.021. Epub 2021 Jan 14. Ann Oncol. 2021. PMID: 33455880 Free article. Review.
The Global Landscape of Treatment Standards for Breast Cancer.
Trapani D, Douillard JY, Winer EP, Burstein H, Carey LA, Cortes J, Lopes G, Gralow JR, Gradishar WJ, Magrini N, Curigliano G, Ilbawi AM. Trapani D, et al. Among authors: curigliano g. J Natl Cancer Inst. 2021 Sep 4;113(9):1143-1155. doi: 10.1093/jnci/djab011. J Natl Cancer Inst. 2021. PMID: 33502535
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials.
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V; COVID19 and Cancer Clinical Trials Working Group. Desai A, et al. Among authors: curigliano g. Nat Rev Clin Oncol. 2021 May;18(5):313-319. doi: 10.1038/s41571-021-00487-z. Epub 2021 Mar 15. Nat Rev Clin Oncol. 2021. PMID: 33723371 Free PMC article. Review.
Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials.
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V; COVID19 and Cancer Clinical Trials Working Group. Desai A, et al. Among authors: curigliano g. Nat Rev Clin Oncol. 2021 May;18(5):320. doi: 10.1038/s41571-021-00503-2. Nat Rev Clin Oncol. 2021. PMID: 33758378 Free PMC article. No abstract available.
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Gainor JF, et al. Among authors: curigliano g. Lancet Oncol. 2021 Jul;22(7):959-969. doi: 10.1016/S1470-2045(21)00247-3. Epub 2021 Jun 9. Lancet Oncol. 2021. PMID: 34118197 Clinical Trial.
751 results